Combinatorial antibodies against human malignant melanoma

Hybridoma

Volumn 16, Issue 1, 1997, Pages 11-16

  Pereira, S ^a   Van Belle, P ^b   Elder, D ^b   Maruyama, H ^a   Jacob, L ^a   Sivanandham, M ^c   Wallack, M ^c   Siegel, D ^b   Herlyn, D ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ST VINCENT S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; MELANOMA ANTIGEN; TUNICAMYCIN;

ANTIBODY PRODUCTION; B LYMPHOCYTE; CASE REPORT; CONFERENCE PAPER; DNA LIBRARY; HUMAN; HUMAN CELL; IMMUNOGENICITY; MALE; MELANOMA; MELANOMA CELL; PHAGE DISPLAY; PRIORITY JOURNAL;

EID: 0030939185     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1997.16.11     Document Type: Conference Paper

References (23)

1. McGee JMC: Immunotherapy for malignant melanoma: A review and update. Semin Surg Oncol 1991;7:217-220.
2. Riethmudie;ller G, Schneider-Gädicke K, Schlimock G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hircke H, Pichlmayr R, Buggisch P, Witte J, and the German Cancer Aid 17-1A Study Group: Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994;343:1177-1183.
3. Livingston PO, Natoli EJ, Calves MJ, Stockert E, Oettgen H, and Old LJ: Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 1987;84:2911-2915.
4. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau H, and Lind S: Active immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988;48:1 858-1867.
5. Mittelman A, Chen ZJ, Yang H, Wong GY, and Ferrone S: Human high molecular weight melanoma-associated antigen (MMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992;89:465-470.
6. Durrant LG, Buckley TJD, Denton GWL, Hardcastle JD, Sewell HF, and Robbins RA: Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7. Cancer Res 1994;54:4837-4840.
7. Sakurai T, Ametani A, Nakamura Y, Shimizu H, Idota T, and Kaminogawa S: Cryptic B cell determinants in a short peptide: T cells do not induce antibody response of B cells when their determinants entirely ovelap each other. Int Immunol 1993;5:793-800.
8. Hamby CV, Liao S-K, Kanamaru T, and Ferrone S: Immunogenicity of human melanoma-associated antigens defined by murine monoclonal antibodies in allogeneic and xenogeneic hosts. Cancer Res 1987;47:5284-5289.
9. Old LJ: Cancer immunology: the search for specificity-G.H.A. Clowes Memorial Lecture. Cancer Res 1981;41:361-375.
10. Hayashibe K, Mishima Y, and Ferrone S: Cloning and in vitro expression of a melanoma-associated antigen immunogenic in patients with melanoma. J Immunol 1991;147:1098-1104.
11. Sugden B, and Mark W: Clonal transformation of adult human leukocytes by Epstein-Barr virus. J Virol 1977;23:503-508.
12. Kozbor D, and Roder JC: Monoclonal antibodies produced by human lymphocytes. Immunol Today 1983;4:72-79.
13. Smith GP: Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surfaces. Science 1985;228:1315-1317.
14. Nissim A, Griffiths AD, Tomkinson IM, Williams SC, Walter G, Cook GP, Hartley O, Waterhouse P, Jones P, Low NH, Cox JPL, Hoogenboom HR, Harrison JL, Prospero T, and Winter G: Mimicking the immune system using phage antibody technology. Tumor Targeting 1995;1:13-16.
15. Parmley SF, and Smith GP: Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 1988;73:305-318.
16. Wallack MK, Scoggin SD, and Sivanandham M: Active specific immunotherapy with vaccinia melanoma oncolysate. The Mount Sinai J Med 1993;59:227-233.
17. Burton DR, Barbas CF, III, Persson MAA, Koenig S, Chanock RM, and Lerner RA: A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Nat Acad Sci USA 1991;88:10134-10137.
18. Chenggis ML, and Unger ER: Application of a manual capillary action workstation to colorimetric in situ hybridization. J Histotechnol 1993;16:33-38.
19. Lezzoni JC, Manahan LJ, Park C, and Brigati DJ: Recent advances in automated immunohistochemistry. J Histotechnol 1993;16:39-50.
20. Wang JY, and Montone KT: A rapid simple in situ hybridization method for herpes simplex virus employing a synthetic biotin-labeled oligonucleotide probe: a comparison with immunohistochemical methods for HSV detection. J Clin Lab Anal 1994;8:105-115.
21. Herlyn D, Pereira S, Maruyama H, Van Belle P, Sivanandham M, Wallack M, Elder D, and Siegel D: Identification of tumor antigens using antibody phage display. In: IBC Biomedical Library Series "Antibody Engineering: New Technologies, Applications, and Commercialization." International Business Communications, Southborough, MA 1996, pp. 90-102.
22. Herlyn D, Pereira S, Maruyama H, Jacob L, Van Belle P, Sivanandham M, Wallack M, Elder D, and Siegel D: Identification of tumor antigens with vaccine potential using antibody phage display. Proc Am Assn Cancer Res 1996;37:479 (Abstract).
23. Robbins PF, EI-Gamil M, Kawakami Y, Stevens E, Yannelli JR, and Rosenberg SA: Recognition of tyrosinase by tumor-infiltrat-ing lymphocytes from a patient responding to immunotherapy. Cancer Res 1994;54:3124-3126.